Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

BACKGROUND Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment. METHODS We developed a sandwich ELISA using recombinant human PCSK9 protein and 2 affinity-purified polyclonal antibodies directed against human PCSK9. We measured circulating PCSK9 concentrations in 115 diabetic patients from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study before and after fenofibrate treatment. RESULTS We found that plasma PCSK9 concentrations correlate with total (r = 0.45, P = 0.006) and LDL (r = 0.54, P = 0.001) cholesterol but not with triglycerides or HDL cholesterol concentrations in that cohort. After 6 weeks of treatment with comicronized fenofibrate (200 mg/day), plasma PCSK9 concentrations decreased by 8.5% (P = 0.041 vs pretreatment). This decrease correlated with the efficacy of fenofibrate, as judged by a parallel reduction in plasma triglycerides (r = 0.31, P = 0.015) and LDL cholesterol concentrations (r = 0.27, P = 0.048). CONCLUSIONS We conclude that this decrease in PCSK9 explains at least in part the LDL cholesterol-lowering effects of fenofibrate. Fenofibrate might be of interest to further reduce cardiovascular risk in patients already treated with a statin.

[1]  Proprotein convertase subtilisin kexin type 9 (PCSK9) , 2010 .

[2]  P. Barter,et al.  Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. , 2008, Atherosclerosis.

[3]  W. Alborn,et al.  Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 Published, JLR Papers in Press, November 21, 2007. , 2008, Journal of Lipid Research.

[4]  P. Barter,et al.  Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[5]  F. Gonzalez,et al.  The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  F. Gonzalez,et al.  The PPARα-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARα , 2008 .

[7]  J. Repa,et al.  Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. , 2007, Journal of lipid research.

[8]  Y. Qian,et al.  Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. , 2007, Clinical chemistry.

[9]  N. Seidah,et al.  Plasma PCSK9 levels correlate with cholesterol in men but not in women. , 2007, Biochemical and biophysical research communications.

[10]  Jennifer L. Harris,et al.  Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. , 2007, The Biochemical journal.

[11]  J. Horton,et al.  Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells* , 2007, Journal of Biological Chemistry.

[12]  R. De Francesco,et al.  Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation* , 2007, Journal of Biological Chemistry.

[13]  Y. Qian,et al.  Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007. , 2007, Journal of Lipid Research.

[14]  Jonathan C. Cohen,et al.  Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* , 2007, Journal of Biological Chemistry.

[15]  G. Lambert.  Unravelling the functional significance of PCSK9 , 2007, Current opinion in lipidology.

[16]  Annik Prat,et al.  The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR , 2007, Traffic.

[17]  N. Walker,et al.  The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. , 2007, Structure.

[18]  Xiayang Qiu,et al.  Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia , 2007, Nature Structural &Molecular Biology.

[19]  B. Monia,et al.  Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007. , 2007, Journal of Lipid Research.

[20]  Jonathan C. Cohen,et al.  Molecular biology of PCSK9: its role in LDL metabolism. , 2007, Trends in biochemical sciences.

[21]  T. Ranheim,et al.  Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly , 2007, BMC Cell Biology.

[22]  R. Hammer,et al.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. , 2006, The Journal of clinical investigation.

[23]  M. Krempf,et al.  Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. , 2006, Endocrinology.

[24]  M. Krempf,et al.  Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c* , 2006, Journal of Biological Chemistry.

[25]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[26]  H. McIntyre,et al.  Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. , 2005 .

[27]  A. Keech,et al.  Fenofibrate Intervention and Event Lowering in Diabetes ( FIELD ) study : baseline characteristics and short-term effects of fenofibrate [ ISRCTN 64783481 ] The FIELD Study Investigators * , 2022 .

[28]  R. Hammer,et al.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Jay D. Horton,et al.  Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver* , 2004, Journal of Biological Chemistry.

[30]  L. Bernier,et al.  Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.